EA-2353, a photoreceptor regeneration treatment for blindness, by Endogena Therapeutics
Labiotech - 12-Jul-2022Endogena's gene-independent treatment has shown advantages in retinitis pigmentosa
Join the club for FREE to access the whole archive and other member benefits.
Professor of Ophthalmology at the Casey Eye Institute Oregon Health & Science University (OHSU) in Oregon
Dr. Mark Pennesi, MD, PhD, is a Professor in Ophthalmology at Oregon Health & Science University. He holds the Kenneth C. Swan Endowed Professorship and is the Chief of the Ophthalmic Genetics Division at the Casey Eye Institute. Dr. Pennesi attended the University of Pennsylvania, where he graduated summa cum laude with a bachelor’s degree in biomedical engineering and was awarded the Herman P. Schwann award in bioengineering for exemplary scholarship. Dr. Pennesi’s interest in degenerative retinal disorders began shortly after his first year in college when he spent a summer working at the Retina Foundation of the Southwest, where he worked under the supervision of Dr. David Birch seeing patients with inherited retinal degenerations, such as retinitis pigmentosa.
Dr. Pennesi pursued a combined MD/PhD at Baylor College of Medicine in Houston, Texas. He received numerous awards while in graduate school, including the John J. Trentin Award for earning the highest GPA in his class and the BRASS scholarship for playing an active role in community service.
He was awarded the Alcon Young Investigator Award in 2014 and a Residency Teaching award in 2015. He has also been elected into both the Macula Society and Retina Society.
Visit website: https://www.ohsu.edu/people/mark-pennesi-md-phd
Details last updated 13-Jul-2022
Endogena's gene-independent treatment has shown advantages in retinitis pigmentosa